SMMTライブシグナル | Getagraph.comで利益を最大化

買う 122575 min ago

@ $4.41

発行日: 15 2月 2024 @ 05:08

リターン: 8.39%

前回のシグナル: 2月 15 - 04:15

前回のシグナル: 売る

リターン: -0.23 %

Live Chart Being Loaded With Signals

Commentary (10 5月 2024 @ 05:00):

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America...

Stats
本日の出来高	2.08M
平均出来高	2.28M
時価総額	3.36B
EPS	$0 ( 2024-05-01 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	12.58
ATR14	$0.0120 (0.25%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-11	Ronaghi Mostafa	Buy	25 315	Stock Option (right to buy)
2024-04-11	Ronaghi Mostafa	Buy	200 000	Stock Option (right to buy)
2024-04-11	Ronaghi Mostafa	Buy	0
2024-04-02	Soni Manmeet Singh	Buy	1 100 000	Stock Option (right to buy)
2024-04-02	Anand Bhaskar	Buy	600 000	Stock Option (right to buy)

INSIDER POWER
99.43
Last 89 transactions
Buy: 581 405 260 \| Sell: 937 995

ボリューム相関

長: -0.39 (neutral)

短: -0.69 (moderate negative)

Signal:(38.676) Neutral

Summit Therapeutics plc 相関

10 最も正の相関
ACST	0.898
TATT	0.892
NPCE	0.892
DRTT	0.89
VSTM	0.884
AVIR	0.881
GLMD	0.881
MREO	0.879
CNXC	0.872
SRPT	0.87

10 最も負の相関
MTEK	-0.922
BFRI	-0.905
CINC	-0.873
SNCR	-0.868
MLVF	-0.862
SLDP	-0.858
LEDS	-0.858
PPBT	-0.858
XPDI	-0.856
PMD	-0.852

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Summit Therapeutics plc 相関 - 通貨/商品

0.00
( neutral )

0.09
( neutral )

0.00
( neutral )

-0.19
( neutral )

0.36
( neutral )

Summit Therapeutics plc 財務諸表

Annual	2023
収益:	$0
総利益:	$-2.05M (0.00 %)
EPS:	$-0.990

FY	2023
収益:	$0
総利益:	$-2.05M (0.00 %)
EPS:	$-0.990

FY	2022
収益:	$704 295
総利益:	$-1.81M (-256.95 %)
EPS:	$-0.380

FY	2021
収益:	$1 809.00
総利益:	$1 809.00 (100.00 %)
EPS:	$-0.000960

Financial Reports:

No articles found.

Summit Therapeutics plc

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.

リアルタイムの更新： Summit Therapeutics plc [SMMT]

Upcoming Earnings Alert